P15391
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
CD19
NCBI Official Synonym Full Names
CD19 molecule
NCBI Protein Information
B-lymphocyte antigen CD19; OTTHUMP00000122551; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
UniProt Protein Name
B-lymphocyte antigen CD19
UniProt Synonym Protein Names
B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12
UniProt Entry Name
CD19_HUMAN
NCBI Summary for CD19
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. [provided by RefSeq]
UniProt Comments for CD19
Function: Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Subunit structure: Forms a complex with CD21, CD81 and CD225 in the membrane of mature B cells. Interacts with VAV. Interacts with GRB2 and SOS when phosphorylated on Tyr-348 and/or Tyr-378. Interacts with PLCG2 when phosphorylated on Tyr-409. Ref.11
Subcellular location: Membrane; Single-pass type I membrane protein.
Post-translational modification: Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. Ref.10 Ref.11 Ref.12
Involvement in disease: Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [
MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low. Ref.13
Sequence similarities: Contains 2 Ig-like C2-type (immunoglobulin-like) domains.
Sequence caution: The sequence AAA35533.1 differs from that shown. Reason: Frameshift at position 396.
Product References and Citations for anti-CD19 antibody
1. McMichael, A.K., P.C.L. Beverly, S. Cobbold, M.J. Crumpton, W. Gilks, F.M. Gotch, N. Hogg, M. Horton, N. Ling, I.C.M. MacLennan, D.Y. Mason, C. Milstein, D. Spiegelhalter, and H. Waldmann, eds. 1987. Leukocyte Typing III: White Cell Differentiation Antigens, Oxford University Press, Oxford. 2. Barclay, A.N., M.H. Brown, S.K.A. Law, A.J. McKnight, M.G. Tomlinson, and P.A. van der Merwe, eds. 1997. The Leukocyte Antigens Facts Book, 2nd Edition, CD19 Section, Academic Press, New York, p. 179. 3. Tedder, T.F., L.J. Zhou, and P. Engel. 1994. Immunol. Today 14:437. 4. Fearon, D.T., and R.H. Carter. 1995. Annu. Rev. Immunol. 13:127. 5. Doody, G.M., P.W. Dempsey, and D.T. Fearson. 1996. Curr. Opin. Immunol. 8:378.
Research Articles on CD19
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-CD19 antibody
Pathways associated with anti-CD19 antibody
Diseases associated with anti-CD19 antibody
Organs/Tissues associated with anti-CD19 antibody
|